Introduction
============

Maintaining the integrity of DNA during transactions such as transcription, replication, and repair is critical for preventing chromosomal mutations, deletions, and rearrangements that may ultimately lead to cancer. Replication of the human genome is a highly complex process that enables the effective and accurate duplication of genetic information. Most crucially, DNA replication is tightly monitored to ensure that the genome is replicated just once per cell cycle and that replication is complete before mitosis begins ([@bib3]). Similarly, cellular responses to DNA double-strand breaks (DSBs) are highly coordinated and involve the sensing of damaged DNA together with signaling to DNA repair, cell-cycle checkpoint, and apoptotic machineries ([@bib9]).

The eukaryotic genome contains numerous natural impediments to replication, including unusual DNA structures, DNA-binding proteins, highly transcribed DNA sequences, and slow replication zones ([@bib3]). Chromosomal fragile sites, which are classified as either rare or common, are specific genomic loci that display gaps or breaks on metaphase chromosomes after partial inhibition of DNA synthesis ([@bib15]). The majority of common fragile sites are induced by treatment with low doses of aphidicolin (APH), an inhibitor of replicative polymerases, which suggests that they arise as a consequence of replication stress ([@bib17]). Common fragile sites have received particular attention in recent years because they are sites of frequent deletions and other chromosome rearrangements in tumor cells ([@bib15]).

p53 binding protein 1 (53BP1) is an important component of the DNA damage response (DDR) that localizes to microscopically visible foci at DSB sites ([@bib38]). Animals or cells lacking 53BP1 are hypersensitive to ionizing radiation, and display DNA damage checkpoint defects and impaired DNA repair ([@bib43]). 53BP1 also plays important roles in class switch recombination at immunoglobulin loci ([@bib27]; [@bib44]; [@bib34]). In addition, loss of 53BP1 leads to impaired distal V-DJ joining ([@bib12]). Furthermore, chromosome fusions of Trf2-uncapped telomeres by classical nonhomologous end-joining (NHEJ) require 53BP1 ([@bib33]). Additionally, defects in distal joining of dysfunctional telomeres via NHEJ are seen in the absence of 53BP1 ([@bib14]). Notably, recent work has shown that 53BP1 deficiency rescues phenotypes associated with BRCA1 dysfunction. Thus, depletion of 53BP1 rescues the proliferation defect observed in *Brca1*-null cells and the hypersensitivity of *Brca1*-null cells to cisplatin and mitomycin C ([@bib2]). Loss of 53BP1 also alleviates the hypersensitivity of *Brca1* mutant cells to PARP inhibition and allows for processing of DNA ends to promote homologous recombination ([@bib4]).

Here, we investigate the accumulation of 53BP1 in large nuclear bodies within a subset of asynchronously growing mammalian cells. Specifically, we reveal that these bodies represent previously characterized OPT (Oct-1, PTF, transcription) domains ([@bib31]), as 53BP1 colocalizes in these structures together with Oct-1 and PTF in G1 cells. In addition to showing that 53BP1-OPT domains represent sites of low transcriptional activity, we establish that their integrity depends on H2AX and the protein kinase activity of ataxia telangiectasia mutated (ATM). Consistent with these data, we demonstrate that 53BP1-OPT domains also contain phosphorylated H2AX (γH2AX) and mediator of DNA damage checkpoint 1 (MDC1), which strongly suggests that these domains represent sites of DNA damage. Finally, we establish that although 53BP1-OPT domains are restricted to G1 cells, their formation is enhanced by exposure of cells to APH. We discuss these findings in relation to the molecular events leading to OPT domain formation and disassembly, as well as their potential functions in maintaining genome integrity.

Results
=======

53BP1 accumulates in nuclear bodies in G1 cells
-----------------------------------------------

Although it is well established that 53BP1 localizes to sites of DNA DSBs generated when cells are treated with DNA damaging agents, we and others have known for several years ([@bib28]; [@bib11]) that 53BP1 localizes to a small number of large (2--3 µm) discrete bodies/foci in the nuclei of tissue culture cells grown under normal conditions ([Fig. 1 A](#fig1){ref-type="fig"}). Because these bodies occur in only a subset of cells within an asynchronously growing population, we explored whether 53BP1 body formation was cell cycle dependent. Thus, we performed immunofluorescence studies in several human and murine cell lines with an antibody against Cyclin A (Cyc A) as a marker of S/G2 phases. Strikingly, the large majority of cells containing large 53BP1 nuclear bodies were Cyc A negative ([Fig. 1 A](#fig1){ref-type="fig"} and not depicted). Furthermore, quantification of Cyc A--negative cells with large 53BP1 bodies in telomerized (human telomerase reverse transcriptase \[hTERT\]) human BJ fibroblasts revealed that 16% of total cells and 21% of Cyc A--negative cells contained such bodies ([Fig. 1 B](#fig1){ref-type="fig"}). Of the Cyc A--negative cells containing 53BP1 bodies, 87% contained one body, whereas 11% and 2% contained two and more than two bodies, respectively ([Fig. 1 B](#fig1){ref-type="fig"}). In parallel studies, we found that 53BP1 nuclear bodies also existed in a subset of quiescent primary human fibroblasts (unpublished data). Collectively, these data revealed that large 53BP1 nuclear bodies occur preferentially in G0 and G1 cells.

![**53BP1 accumulates in nuclear bodies in a subset of G1 cells.** (A) Asynchronously growing BJ hTERT cells were fixed, and immunofluorescence was performed with mouse anti-53BP1 and rabbit anti--Cyc A antibodies. (B, left) Quantitation of total or Cyc A--negative cells from A that contained 53BP1 nuclear bodies. Results represent the mean ± SD from three experiments (total, *n* = 4,944; Cyc A negative, *n* = 3,956). (B, right) Quantitation of Cyc A--negative cells from A that contained 53BP1 bodies. Results represent the mean ± SD from three experiments (*n* = 829). We note that 53BP1 foci were also observed in 10.8% (±2.8%) of Cyc A--positive cells (not depicted), which likely represent early-to-mid S phase cells (see D). (C) Live cell imaging of U2OS cells stably expressing EGFP-53BP1 from mitosis into G1. (D) BJ hTERT cells were pulsed with EdU for 10 min, fixed, and stained with rabbit anti-53BP1 antibodies. EdU was visualized using click chemistry. (E) Live cell imaging of U2OS cells stably expressing EGFP-53BP1 and mRuby-PCNA from G1 into S phase. Bars: (A and C) 30 µm; (D and E) 10 µm.](JCB_201011083_RGB_Fig1){#fig1}

To further characterize the formation of 53BP1 nuclear bodies in G1, we used human U2OS cells stably expressing 53BP1 fused to EGFP. Live cell imaging revealed that when 53BP1 bodies arose, they did so almost immediately after a mitotic cell entered G1 phase, and that in most cases (\>90%), the bodies arose in parallel within both daughter cells ([Fig. 1 C](#fig1){ref-type="fig"}). Furthermore, when we pulsed cells with 5-ethynyl-2′-deoxyuridine (EdU) to mark sites of DNA replication, we observed that 53BP1 bodies were invariably EdU negative ([Fig. 1 D](#fig1){ref-type="fig"}). In accordance with our other data, this analysis revealed that although no large 53BP1 bodies were present in S phase cells, smaller 53BP1 nuclear foci existed in a fraction of early S phase cells (14%) and mid S phase cells (3%) but were absent in late S phase cells ([Fig. 1 D](#fig1){ref-type="fig"}). Collectively, these findings suggested that 53BP1 nuclear bodies are either removed, or do not form effectively, in mid or late S phase cells. This conclusion was supported by live imaging studies of U2OS cells stably expressing EGFP-53BP1 and mRuby-PCNA, where we observed that large nuclear 53BP1 bodies present in G1 cells gradually disappeared as S phase progression ensued ([Fig. 1 E](#fig1){ref-type="fig"}).

53BP1 is a component of OPT domains
-----------------------------------

To determine whether 53BP1 nuclear bodies are related to one of the various subnuclear bodies/domains that have been previously documented ([@bib41]), we used antibodies specific for such domains to see whether they colocalized with 53BP1. Thus, by staining with an antibody against fibrillarin, we found that 53BP1 nuclear bodies did not reside in the nucleolus and that, in fact, 53BP1 nuclear staining was consistently excluded from the nucleolus ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201011083/DC1)). In addition, we found that 53BP1 bodies did not colocalize with Cajal bodies as detected by coilin staining. Furthermore, 53BP1 nuclear bodies were not components of splicing speckles containing the SC-35 protein, although we did note that 53BP1 bodies frequently had SC-35 staining adjacent to them (Fig. S1).

As 53BP1 nuclear bodies are quite large in size (2--3 µm) and are cell cycle regulated, we explored whether they might correspond to OPT domains that share similar size and cell cycle characteristics, and which contain the transcription factors Oct-1 and PTF ([@bib31]). Strikingly, we observed that 53BP1 nuclear bodies colocalized with staining produced by antibodies against Oct-1 and two different subunits of PTF (PTFδ and PTFγ) in BJ fibroblasts ([Fig. 2 A](#fig2){ref-type="fig"}). Consistent with earlier work ([@bib31]), we also found that a PML body often resided at the periphery of, or was contained within, 53BP1 nuclear bodies ([Fig. 2 A](#fig2){ref-type="fig"}). In addition, similar colocalizations between 53BP1 and Oct-1, PTFδ, or PML were observed in U2OS cells ([Fig. 2 B](#fig2){ref-type="fig"}). Collectively, these results established that 53BP1 is a component of the previously described OPT domain. While surveying for additional colocalizing factors, we found that the DEAD box RNA/RNA and RNA/DNA helicase DDX1 also localized with 53BP1 nuclear bodies ([Fig. 2 C](#fig2){ref-type="fig"}), showing that previously characterized DDX1 bodies ([@bib24]) in G1 cells are also components of 53BP1-OPT domains.

![**53BP1 colocalizes with components of OPT domains.** (A) Immunofluorescence was performed in BJ primary or BJ hTERT (PTFγ) fibroblasts with mouse anti-53BP1 and rabbit anti--Oct-1, anti-PTFδ, or anti-PTFγ, and rabbit anti-53BP1 and mouse anti-PML antibodies as indicated. Analysis of \>100 cells revealed that 88% of 53BP1 nuclear bodies contained at least one PML body. (B) Experiments were performed as in A with U2OS cells and the indicated antibodies. (C) Immunofluorescence was performed in BJ primary fibroblasts with mouse anti-53BP1 and rabbit anti-DDX1 antibodies. (D) BJ hTERT fibroblasts were exposed to 1.5 Gy of ionizing radiation and fixed 1 h later. Immunofluorescence was performed with rabbit anti-PTFδ and mouse anti-53BP1 antibodies. Bars, 10 µm.](JCB_201011083_RGB_Fig2){#fig2}

53BP1-OPT domains require DNA damage signaling and exhibit low transcription levels
-----------------------------------------------------------------------------------

Previous work has established that DNA DSBs trigger activation of the phosphoinositide 3-kinase--related protein kinases (PIKKs) ATM, ATR, and DNA-PK ([@bib22]; [@bib26]), which then phosphorylate various proteins, including the histone variant H2AX. γH2AX then recruits MDC1, which is required for the effective accumulation and retention of 53BP1 at DSB sites ([@bib5]; [@bib42]). Notably, we found that 53BP1-OPT domains colocalized with both γH2AX and MDC1 ([Fig. 3 A](#fig3){ref-type="fig"}), which strongly suggests that they correspond to sites of DNA damage. In accord with this, the proportion of cells with 53BP1 nuclear bodies in Cyc A--negative cells was substantially lower in H2AX*^−/−^* mouse embryonic fibroblasts (MEFs) than in wild-type controls ([Fig. 3 B](#fig3){ref-type="fig"}). In addition, we found that 53BP1 nuclear bodies, as detected by 53BP1 staining ([Fig. 3 C](#fig3){ref-type="fig"}) or staining with other OPT domain components (PTFδ and PML; [Fig. 3 D](#fig3){ref-type="fig"}), were largely abrogated when asynchronously growing BJ cell populations were incubated with the ATM inhibitor KU-55933 ([@bib18]). In contrast, we found that 53BP1 formed large nuclear bodies that colocalized with PTFδ and PML within Cyc A--negative ATR-deficient Seckel cells ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201011083/DC1)). However, we note that immunofluorescence studies revealed the presence of OPT domains, albeit smaller in size, in both ATM-deficient AT cells and ATM*^−/−^* MEFs (unpublished data), which suggests that, although OPT domain formation is largely ATM dependent, other PIKKs such as DNA-PK and/or ATR are also likely to contribute, particularly when ATM is absent. Collectively, these data strongly suggested that 53BP1-OPT domains represent sites of endogenously arising DNA damage in G1 cells. In line with this idea, we found that Oct-1, PTFδ, and PTFγ were recruited to tracts of DNA damage produced by laser micro-irradiation ([Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201011083/DC1)). PTFδ also formed foci that colocalized with 53BP1 in cells treated with ionizing radiation ([Fig. 2 D](#fig2){ref-type="fig"}), whereas PML did not (Fig. S3 B). These results thus provided additional support for OPT domains being sites of DNA damage and suggested roles for various OPT domain components in the DDR.

![**53BP1-OPT domains represent sites of DNA damage.** (A) Immunofluorescence was performed in BJ hTERT fibroblasts with rabbit anti-53BP1 and mouse anti-γH2AX (top) or mouse anti-53BP1 and rabbit anti-MDC1 pSDTD (bottom) antibodies. (B, left) Immunofluorescence was performed in H2AX*^+/+^* or H2AX*^−/−^* MEFs with rabbit anti-53BP1 or mouse anti--Cyc A antibodies. (B, right) Quantitation of Cyc A--negative cells that contained 53BP1 nuclear bodies. Results represent the mean ± SD from three experiments (H2AX*^+/+^*, *n* = 636; H2AX*^−/−^*, *n* = 384). (C, left) BJ hTERT fibroblasts were incubated in the absence (Cont) or presence of ATM inhibitor KU55933 (ATMi; 20 µM) for 3 h. Immunofluorescence was performed with mouse anti-53BP1 and rabbit anti--Cyc A antibodies. (C, right) Quantitation of Cyc A--negative cells that contained 53BP1 nuclear bodies. Results represent the mean ± SD from three experiments (Cont, *n* = 522; ATMi, *n* = 491). (D) Experiments were performed as in C and immunofluorescence was performed with rabbit anti-PTFδ and mouse anti-53BP1 antibodies (left) or mouse anti-PML and rabbit anti-53BP1 antibodies (right). Bars: (A) 10 µm; (B--D) 30 µm.](JCB_201011083_RGB_Fig3){#fig3}

Recent work has shown that transcription is inhibited at DNA DSB sites by mechanisms requiring ATM kinase activity ([@bib40]). Consistent with 53BP1-OPT domains in G1 cells corresponding to DNA damage sites, they did not colocalize with initiating or elongating forms of RNA polymerase II (Pol II), as detected by antibodies recognizing phosphorylated Ser-5 (pS5) and Ser-2 (pS2) within the C-terminal domain of the Pol II large subunit ([Fig. 4 A](#fig4){ref-type="fig"}). Moreover, when we used incorporation of 5-fluorouridine (FlU) to detect sites of active transcription, this revealed that 53BP1-OPT domains were largely devoid of FIU staining ([Fig. 4 B](#fig4){ref-type="fig"}). In addition, we observed that 53BP1 nuclear bodies were lost when cells were treated with DNase I but not RNase A before immunofluorescence staining ([Fig. 4 C](#fig4){ref-type="fig"} and not depicted). Collectively, these results demonstrated that 53BP1-OPT domains associate with DNA but do not correspond to sites of detectable transcription.

![**53BP1-OPT domains do not associate with regions of active transcription and are dependent on DNA.** (A) Immunofluorescence was performed in BJ primary fibroblasts with mouse anti-53BP1 and rabbit anti-Pol II pS2 (top) or rabbit anti-53BP1 and mouse anti-Pol II pS5 (bottom) antibodies. (B) BJ primary fibroblasts were incubated for 60 min with FlU and immunofluorescence was performed with rabbit anti-53BP1 and mouse anti-BrdU antibodies. (C) BJ primary fibroblasts were incubated in the absence or presence of DNase I as indicated for 10 min. Immunofluorescence was performed with rabbit anti-53BP1 or mouse anti--Lamin A/C antibodies. DAPI and Lamin A/C were positive and negative controls, respectively. Bars, 10 µm.](JCB_201011083_RGB_Fig4){#fig4}

Links between 53BP1-OPT domains and chromosomal fragile sites
-------------------------------------------------------------

To determine whether OPT domains containing 53BP1 are preferentially associated with particular chromosomal regions, we performed DNA immuno-FISH experiments. By using whole chromosome paints specific for seven different chromosomes, we found that 53BP1-OPT domains colocalized with chromosome 2 in ∼45% of cells with these domains ([Fig. 5 A](#fig5){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}). These data were therefore consistent with a previous study by [@bib31], which showed that PTF domains displayed the highest level of colocalization with chromosome 2. Furthermore, our analyses revealed that \>30% of cells containing 53BP1-OPT domains colocalized with chromosomes 3, 6, or 7 ([Fig. 5 A](#fig5){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}).

###### 

Frequency of association between chromosomes and 53BP1-OPT domains

  Chromosome number   Chromosome size   Colocalization with 53BP1-OPT domains   No colocalization with 53BP1-OPT domains
  ------------------- ----------------- --------------------------------------- ------------------------------------------
                      *Mb*              *%*                                     *%*
  2                   243               45 (*n* = 168)                          55 (*n* = 203)
  3                   198               41 (*n* = 129)                          59 (*n* = 188)
  6                   171               32 (*n* = 113)                          68 (*n* = 241)
  7                   159               36 (*n* = 105)                          64 (*n* = 194)
  14                  107               26 (*n* = 79)                           74 (*n* = 235)
  16                  90                27 (*n* = 99)                           73 (*n* = 261)
  17                  81                24 (*n* = 81)                           76 (*n* = 254)

Results represent the average of two independent experiments. *n* = number of cells analyzed.

![**γH2AX accumulates at discrete regions of the genome in untreated cells.** (A) DNA Immuno-FISH was performed in BJ hTERT fibroblasts with anti-53BP1 antibodies and whole chromosome paints. (A, left) Colocalization between 53BP1 nuclear bodies and chromosome regions. (A, right) No colocalization between 53BP1 nuclear bodies and chromosome regions. Bar, 10 µm. (B) ChIP-seq experiments were performed with serum-starved (G0) BJ hTERT fibroblasts and γH2AX antibodies. The eight highest peaks for γH2AX enrichment are displayed along with the negative control (IgG). Data are shown as custom tracks (bin 20) on the UCSC genome browser (data correspond to the Feb. 2009 GRCh37/hg19 genome assembly). The axis scales are presented on the left and chromosome position at the top.](JCB_201011083_RGB_Fig5){#fig5}

To more precisely map the genomic regions containing OPT domains, we performed chromatin immunoprecipitation experiments followed by massively parallel sequencing (ChIP-seq; [@bib35]). Because we have observed that the majority of 53BP1 is chromatin bound (resistant to extraction with 400 mM salt) even when cells are grown in the absence of DNA damaging agents (unpublished data) and because cells containing OPT domains only represent a minority (∼16%) of the total cell population, we reasoned that ChIP-seq analysis of 53BP1 itself would not be OPT domain specific. Therefore, we performed experiments on serum-starved BJ hTERT fibroblasts with antibodies against γH2AX, as this phospho-epitope is highly specific to OPT domains in G0 cells that have not been treated with a DNA damaging agent. By comparing data sets derived from immunoprecipitated γH2AX samples with those from control immunoglobulin immunoprecipitations, we found that γH2AX was specifically associated with various specific regions of the genome in G0 arrested cells ([Fig. 5](#fig5){ref-type="fig"} and [Table II](#tbl2){ref-type="table"}). The genomic locations of the top eight γH2AX-association peaks (as determined by fold enrichment) were located on chromosomes 1 (1q23.2), 2 (2p24.2), 7 (7p13, 7q22.3), 9 (9q33.3), 19 (19p13.3), 20 (20q13.33), and 21 (21q22.3), with four of these peaks corresponding to known common fragile sites (FRA2C, FRA7D, FRA7F, and FRA19B; [@bib39]; [@bib15]). Collectively, the DNA immuno-FISH and ChIP-seq results therefore indicated enhanced associations of OPT domains with chromosomes 2 and 7 in human fibroblasts and, moreover, suggested that these domains preferentially localize to chromosomal fragile sites.

###### 

ChIP-seq peaks for γH2AX

  Chromosome number   Start position   End position   Chromosome position   Fragile site
  ------------------- ---------------- -------------- --------------------- --------------
  1                   79171862         79172697       1p31.1                
  1                   160068001        160069262      1q23.2                
  1                   180991672        180992627      1q25.3                FRA1G
  2                   17699186         17700299       2p24.2                FRA2C
  2                   196527371        196527999      2q32.3                
  2                   242823452        242824274      2q37.3                FRA2J
  4                   155337857        155338768      4q31.3                
  5                   54095885         54096590       5q11.2                
  5                   148822299        148823429      5q32                  
  6                   37137202         37138474       6p21.2                
  7                   6542950          6544002        7p22.1                FRA7B
  7                   43622016         43623713       7p13                  FRA7D
  7                   105751952        105753887      7q22.3                FRA7F
  8                   143858334        143859358      8q24.3                FRA8D
  9                   129986095        129988041      9q33.3                
  10                  99599623         99600560       10q24.2               
  11                  133906686        133907757      11q25                 
  12                  117565420        117567081      12q24.22              
  16                  2954968          2956441        16p13.3               
  16                  22201426         22202642       16p12.2               
  17                  15163610         15165033       17p12                 FRA17A
  17                  17109369         17110420       17p11.2               
  17                  70404690         70406426       17q24.3               
  17                  73829429         73831182       17q25.1               
  17                  75276722         75278117       17q25.2               
  19                  1122785          1123630        19p13.3               FRA19B
  19                  4327867          4329218        19p13.3               FRA19B
  19                  53030425         53031358       19q13.4               
  20                  61424927         61426403       20q13.33              
  20                  62272821         62273976       20q13.33              
  21                  46824896         46826026       21q22.3               
  22                  45636492         45637492       22q13.31              FRA22A

Chromosomal fragile sites are induced by treating cells with low doses of APH, whereas other replication-inhibiting drugs such as hydroxyurea (HU) are less specific at inducing common fragile site lesions ([@bib15]). Thus, we hypothesized that DNA damage arising from unreplicated or partially replicated genomic regions might be responsible for the formation of 53BP1-OPT domains in G1 cells. Consistent with this, incubation of cells for 24 h with a low concentration of APH (0.4 µM) produced a marked increase in both the proportion of Cyc A--negative cells containing 53BP1 nuclear bodies and the number of these bodies per cell ([Fig. 6, A and B](#fig6){ref-type="fig"}). We note that under these conditions, ∼8% of Cyc A--positive cells also contained 53BP1 foci. Low APH doses also increased the number of PTFδ domains, which colocalized with 53PB1, as well as an increased association of 53BP1 with PML bodies ([Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201011083/DC1)). Treatment of cells with a higher dose of APH (4 µM) produced similar results (unpublished data), although the ensuing numbers of 53BP1 nuclear bodies per cell were even higher.

![**Replication perturbation by APH promotes formation of 53BP1-OPT domains.** (A) BJ hTERT fibroblasts were incubated in the absence (Cont) or presence of APH (0.4 µM, 24 h) as indicated. Immunofluorescence was performed using mouse anti-53BP1 and rabbit anti--Cyc A antibodies. Bar, 30 µm. (B, left) Quantitation of total or Cyc A--negative cells from A that contained 53BP1 nuclear bodies. Results represent the mean ± SD from three experiments (total: Cont, *n* = 1,329; APH, *n* = 1,291; Cyc A negative: Cont, *n* = 987; APH, *n* = 843). (B, right) Quantitation of Cyc A--negative cells from A that contained 53BP1 nuclear bodies. Results represent the mean ± SD from three experiments (Cont, *n* = 199; APH, *n* = 328). (C) BJ hTERT fibroblasts were incubated in the absence (Cont) or presence of HU for 24 h as indicated. Immunofluorescence was performed as described in A and quantified as in B. Results represent the mean ± SD from three experiments. (D) FACS analysis of cells incubated in the absence or presence of APH or HU as indicated. (E) Cellular lysates from cells treated with APH or HU as in A and C were separated by SDS-PAGE, and Western blotting was performed with antibodies against FANCD2 and PARP-1 (loading control).](JCB_201011083_RGB_Fig6){#fig6}

In contrast to our observations after APH treatment, incubation with HU did not significantly affect the incidence of 53BP1-OPT domains as a percentage of total cells, or the number of these domains per cell. However, a slightly increased proportion of Cyc A--negative cells displaying 53BP1-OPT domains was observed after HU treatment ([Fig. 6 C](#fig6){ref-type="fig"}). Importantly, the differences observed between APH and HU did not reflect differences in the extent of S phase perturbation, as both agents caused a similar accumulation of cells in S/G2 phase (from 27% in control cells to 46% and 52% in APH- and HU-treated cells, respectively), as determined by flow cytometry ([Fig. 6 D](#fig6){ref-type="fig"}). Furthermore, as shown in [Fig. 6 E](#fig6){ref-type="fig"}, incubation with either agent resulted in a marked increase in the mono-ubiquitylation of FANCD2, a well-characterized marker of replication stress ([@bib19]). Thus, although exposure to both APH and HU partially inhibited DNA synthesis, only APH treatment increased the number of 53BP1-OPT domains in G1 cells. Collectively, our findings thereby indicated that 53BP1-OPT domains represent genomic loci that exhibit intrinsic replication difficulties, such as common fragile sites.

Discussion
==========

We have established that 53BP1 is a new component of previously characterized OPT domains ([@bib31]), as it colocalizes with Oct-1 and PTF in large nuclear bodies of G1 cells. Consistent with what has been reported for OPT domains ([@bib31]), we found that 53BP1 nuclear bodies form early in G1 and then dissociate as cells enter and progress through S phase. Moreover, we show that localization of 53BP1 to OPT domains depends on H2AX and is largely abrogated by ATM inhibition, which, together with the colocalization of 53BP1-OPT domains with γH2AX and MDC1, strongly suggests that these domains arise at sites of DNA damage. Although the presence of transcription factors Oct-1 and PTF in OPT domains has been taken as evidence that these represent sites of active transcription ([@bib31]), we find that 53BP1-OPT domains are largely devoid of the phosphorylated, elongating forms of Pol II, and lack detectable transcription as assessed by FlU labeling. These data are therefore in line with recent studies showing that DNA damage causes localized inhibition of transcription ([@bib20]; [@bib40]). In this regard, it is noteworthy that we have found that the RNA helicase DDX1 resides in 53BP1-OPT domains, and that this factor localizes to sites of DNA damage that do not contain newly synthesized RNA ([@bib25]). Collectively, our results therefore demonstrate that OPT domains contain DNA damage signaling proteins and therefore likely mark sites of DNA damage.

In light of our data indicating that 53BP1-OPT domains are induced by APH and enriched at certain chromosomal fragile sites, we suggest that 53BP1-OPT domains assemble on, and arise as a consequence of, sites of impaired replication from the previous S phase. Such incompletely replicated regions could arise through the actions of drugs such as APH, endogenously arising DNA damaging agents, or because of intrinsic replication difficulties at particular genomic loci. In this regard, it is noteworthy that recent work from [@bib7] has shown that APH treatment induces FANCD2 sister foci in metaphase chromosomes that colocalize with fragile site loci. Furthermore, ∼10% of the FANCD2 sister foci observed in metaphase cells associate with Bloom syndrome helicase (BLM)-coated ultrafine bridges during anaphase ([@bib7]). Collectively with these findings, our data suggest a model whereby certain regions of the genome, particularly those associated with chromosomal fragile sites, may remain unreplicated during S phase. Such regions would then be bound by the Fanconi anemia proteins FANCD2 and FANCI during G2 phase and upon entry into mitosis. During anaphase, BLM, together with topoisomerase IIIa and hRMI1, would then resolve the partially replicated, hemicatenated DNA ([@bib6]), and upon entry into G1, the unreplicated DNA intermediate would be recognized as DNA damage, resulting in the establishment of 53BP1-OPT domains.

Although the above model suggests that the OPT domains would contain large stretches of single-stranded DNA (ssDNA), we note that we have not been able to detect the presence of ssDNA in 53BP1-OPT domains by immunofluorescence staining for RPA or for BrdU incorporation under nondenaturing conditions ([@bib37]; unpublished data). Thus, if ssDNA does exist in 53BP1-OPT domains, it must either be bound by proteins that we have not yet examined and/or must adopt secondary structures that preclude ssDNA detection. In this regard, we note that the ssDNA overhang of telomeres is bound by protein components of the Shelterin complex and is sequestered by the formation of a T-loop ([@bib30]). We therefore speculate that the sequestration of ssDNA regions within 53BP1-OPT domains may provide a mechanism to prevent their repair by relatively error-prone gap-filling polymerases in G1 and allow progression into S phase, where such stretches of ssDNA could then be faithfully filled in by replicative polymerases. Nevertheless, we are unable to exclude the possibility that, during the segregation of chromosomes during mitosis, unreplicated regions that are not resolved instead result in DNA DSBs. If this is the case, the persistence of OPT domains throughout G1 would imply that such DSBs are not repaired in G1, possibly because they require processing by factors that are not present in G1 or require modification by cyclin-dependent kinases as cells progress from G1 into S phase. Whatever the case, our data yield a model in which impaired DNA synthesis during S phase leads to activation of a DDR and the formation of 53BP1-OPT domains in the subsequent G1 in order to maintain genome integrity.

Materials and methods
=====================

Cell culture and treatments
---------------------------

Human BJ primary fibroblasts, BJ hTERT immortalized fibroblasts, and Seckel cells were cultured in DME (Invitrogen) supplemented with 15% FBS, penicillin, streptomycin, glutamine, and fungazone (PSQF). Human U2OS osteosarcoma cells and H2AX*^−/−^* and H2AX*^+/+^* MEFs (provided by A. Nussenzweig, National Cancer Institute, National Institutes of Health, Bethesda, MD) were maintained in DME plus 10% FBS and PSQF. U2OS cells stably expressing pEGFP-53BP1 ([@bib16]) were grown in DME plus 10% FBS, PSQF, and G418 (500 µg/ml). U2OS cells stably expressing EGFP-53BP1 and mRuby-PCNA (provided by P. Marco-Casanova, The Gurdon Institute, University of Cambridge, Cambridge, England, UK) were grown in DME plus 10% FBS, PSQF, G418 (500 µg/ml), and 0.25 µg/ml puromycin.

Cells were incubated with APH (Sigma-Aldrich) or HU (Sigma-Aldrich) for 24 h as indicated. For inhibition of ATM, cells were incubated with the specific ATM inhibitor KU55933 ([@bib18]) at 20 µM for 3 h before fixation. To identify transcriptionally active regions, cells were incubated with 5 mM FlU (Sigma-Aldrich) for 60 min before fixation. Cells were irradiated using a Faxitron x-ray cabinet at 3.15 Gy/min.

Immunofluorescence microscopy
-----------------------------

Cells were grown on glass coverslips and fixed with one of the following methods: ice-cold MeOH/acetone for 10 min at RT, 2% paraformaldehyde (PFA) for 15 min at RT followed by incubation with 0.5% Triton X-100 in PBS for 10 min at RT, 4% formaldehyde (FA; Sigma-Aldrich) in PBS for 15 min at RT followed by incubation with 0.5% Triton X-100 in PBS for 10 min at RT, or pre-extraction buffer (25 mM Hepes, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl~2~, 300 mM sucrose, and 0.5% Triton X-100) for 5 min at RT followed by fixation with 2% PFA for 15 min at RT. After fixation, cells were washed with PBS and blocked with either 5% FBS in PBS or 5% BSA in PBS. Cells were incubated with primary antibodies (1 h at RT or overnight at 4°C) in blocking buffer, washed with PBS, and then incubated with Alexa Fluor 488 goat anti--mouse/rabbit and Alexa Fluor 594 goat anti--mouse/rabbit (Invitrogen) for 1 h at RT in blocking buffer. DNA was counterstained with DAPI in Vectashield mounting agent (Vector Laboratories). Images were acquired using a laser scanning system (Radiance 2100; Bio-Rad Laboratories) on a microscope (Eclipse E800 upright; Nikon) using a 40× objective lens and Lasersharp 2000 software (Carl Zeiss, Inc.).

For DNase treatments, cells grown on coverslips were washed with CSK buffer (10 mM Pipes, pH 7, 100 mM NaCl, 300 mM sucrose, and 3 mM MgCl~2~) and incubated with CSK buffer plus 0.5% Triton X-100 in the absence or presence of DNase I (Roche; 200 U/ml in 10 mM Hepes, pH 7.4, 50 mM KCl, 10% glycerol, and 1.5 mM MgCl~2~) for 10 min at RT. Coverslips were subsequently washed and fixed with 4% FA in PBS for 15 min at RT, and immunostained as described above.

To detect S phase cells by EdU labeling, BJ hTERT cells were grown on glass coverslips and pulse-labeled for 10 min by supplementing the cell culture medium with 50 µM EdU (Invitrogen). The cells were fixed for 10 min with 4% FA in PBS and permeabilized with 0.5% Triton X-100/PBS for 10 min at RT. EdU was stained with Alexa Fluor 594 azide (Invitrogen) via click chemistry reaction ([@bib36]) broadly following the manufacturer's recommendations as described previously ([@bib13]).

Laser micro-irradiation was used to generate localized damage in cellular DNA by exposure to a UV-A laser beam as described previously ([@bib1]). In brief, cells were plated on glass-bottomed dishes (WillCo) and sensitized with 10 µM BrdU (Sigma-Aldrich) in phenol red--free medium (Invitrogen) for 24 h at 37°C. Laser micro-irradiation was performed on a confocal microscope (FluoView 1000; Olympus) equipped with a 37°C heating stage (Ibidi) and a 405-nm laser diode (6 mW, SIM scanner) focused through a 60× UPlan-SApochromat/1.35 NA oil objective lens to yield a spot size of 0.5--1 µm. After 1 h, cells were fixed and immunostained as indicated.

Antibodies used for immunofluorescence were: 53BP1 (mouse; a gift from T. Halazonetis, University of Geneva, Geneva, Switzerland), 53BP1 (mouse; a gift from J. Chen, University of Texas MD Anderson Cancer Center, Houston, TX), 53BP1 (rabbit, NB100-304; Novus Biologicals), Cyc A (rabbit, H432; Santa Cruz Biotechnology, Inc.), Cyc A (mouse; CRUK), Oct-1 ([@bib46]), PTFδ ([@bib31]), PML (mouse, PG-M3; Santa Cruz Biotechnology, Inc.), PTFγ (rabbit, CS48; a gift from N. Hernandez, University of Lausanne, Lausanne, Switzerland), DDX1 ([@bib25]), γH2AX (mouse, 05-636; Millipore), MCD1 pSDTD ([@bib8]), fibrillarin (mouse; Millipore), SC-35 (mouse; Sigma-Aldrich), coilin (rabbit, H-300; Santa Cruz Biotechnology, Inc.), Pol II pS2 (rabbit, ab5095; Abcam), Pol II pS5 (mouse, ab5408; Abcam), BrdU (mouse, B8434; Sigma-Aldrich), and Lamin A/C (mouse, ab40567; Abcam).

Live cell imaging
-----------------

For live cell imaging of U2OS cells stably expressing EGFP-53BP1, cells were imaged with an ImageXpress Micro System (Molecular Devices) fitted with a 20× lens and equipped with a 37°C heating chamber supplied with CO~2~. Images were acquired with MetaExpress software. U2OS cells stably expressing EGFP-53BP1 and mRuby-PCNA were plated on glass-bottomed dishes (WillCo) in Leibovitz's L15 medium (Invitrogen) containing 10% FBS, and images were acquired with a DeltaVision microscope (Applied Precision) equipped with a 37°C heating chamber, a 40× objective lens, and SoftWoRx software. Images were deconvolved after acquisition.

3D DNA immuno-FISH
------------------

DNA FISH on 3D preserved nuclei was performed by broadly following a published protocol ([@bib10]). In brief, BJ hTERT cells grown on glass coverslips were fixed for 10 min with 4% FA in PBS, permeabilized with 0.5% Triton X-100/PBS for 10 min at RT, and then incubated with RNase A (Sigma-Aldrich; 200 µg/ml in PBS) for 1--2 h at 37°C. Human chromosomes 2, 3, 6, 7, 14, 16, and 17 were detected with directly labeled (green fluorophore) whole chromosome painting probes (Aquarius liquid format) obtained from Cytocell. Cellular DNA and the DNA FISH probes were denatured for 3 min, and hybridization was performed for 16--24 h at 37°C. Coverslips were washed at 37°C twice for 10 min each, with 50% formamide/2× saline-sodium citrate (SSC), 0.05% Tween-20/2× SSC, and 0.2× SSC. 53BP1 was then detected with a rabbit polyclonal antibody (Novus Biologicals) and Alexa Fluor 594--conjugated goat anti--rabbit antibody (Invitrogen).

ChIP-seq
--------

In vivo cross-linking, chromatin purification, and immunoprecipitations were performed essentially as described previously ([@bib29]) with the following modifications. BJ hTERT fibroblasts were serum-starved (DME containing 0.5% FBS plus PSQF). Subsequently, cells were cross-linked for 15 min at RT. Nuclei were resuspended in sonication buffer (50 mM Tris, pH 8, 1% SDS, and 10 mM EDTA) and sonicated with a Bioruptor (Diagenode) at 30-s intervals. ChIP was performed with rabbit IgG (Santa Cruz Biotechnology, Inc.) or rabbit anti-γH2AX (07-164; Millipore) and Protein G--Sepharose beads (Sigma-Aldrich). DNA was eluted in a buffer containing 1% SDS and 100 mM NaHCO~3~. After RNase and Proteinase K treatment, DNA was purified with a QIAquick PCR purification kit (QIAGEN). Libraries for ChIP-seq were generated with a kit essentially as described by the manufacturer (Illumina, Inc.). Amplified DNA was run on 2% agarose gels and stained with SYBR green I (Invitrogen). Bands between 100 and 300 bp were excised, gel purified, and submitted to the Cambridge Research Institute (CRI) for sequencing. Resulting reads were mapped against the human genome (GRCh37) with bwa ([@bib23]). Reads with bwa quality scores \>13 were extended to the mean library length (200 bp). Resulting data were binned to 20-bp regions for display on the UCSC Genome Browser ([@bib21]). Peaks were called using MACS 1.3.7 ([@bib45]) and HPeaks 1.1 ([@bib32]) with IgG and γH2AX as negative and positive controls, respectively. The intersection of overlapping peaks from both peak callers was used as a guide for visual inspection of the peaks. A final list of peaks was generated after the removal of false positives.

Flow cytometry
--------------

Cells were harvested by trypsinization, pelleted, resuspended in PBS, and fixed with cold 70% ethanol. The next day, cells were pelleted and resuspended in PBS containing 250 µg/ml RNase A and 10 µg/ml propidium iodide and incubated for 30 min at 37°C. Cells were analyzed with a FACSCalibur (Beckman Coulter) using CellQuest software.

Western immunoblotting
----------------------

Cells were washed with PBS, scraped in Laemmli buffer (120 mM Tris, pH 6.8, 4% SDS, and 20% glycerol), boiled for 5 min at 95°C, and syringed. Lysates were loaded on a 3--8% Tris-Acetate ([Fig. 6 E](#fig6){ref-type="fig"}) or 4--12% Tris-Glycine (Fig. S2 B) gel (Invitrogen), and proteins were transferred onto a polyvinylidene fluoride membrane. The membrane was blocked with 5% nonfat milk in TBS-T and incubated with primary antibodies for 1 h at RT. After washes with TBS-T, the membrane was incubated with the corresponding horseradish peroxidase--conjugated secondary antibodies for 1 h at RT. Antigen--antibody complexes were detected by enhanced chemiluminescence by ECL (GE Healthcare). Antibodies used for Western blotting were: ATR (goat, N19; Santa Cruz Biotechnology, Inc.), FANCD2 (mouse, FI17; Santa Cruz Biotechnology, Inc.), GRB2 (mouse; BD), or PARP-1 (rabbit, 9542; Cell Signaling Technology).

Online supplemental material
----------------------------

Fig. S1 shows that 53BP1 nuclear bodies do not colocalize with fibrillarin, coilin, or SC-35. Fig. S2 demonstrates that 53BP1-OPT domains form in ATR-deficient Seckel cells. Fig. S3 demonstrates that Oct-1 and PTF localize to sites of DNA damage formed by laser micro-irradiation. Fig. S4 shows an increase in the number of PTFδ and PML bodies that colocalize with 53BP1 after treatment of cells with a low dose of APH. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201011083/DC1>.
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